Department of Pharmacy Practice & Administrative Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA.
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):193-203. doi: 10.1038/pcan.2013.3. Epub 2013 Feb 12.
To our knowledge, no previous study has examined state-level geographic variability and its predictors in clinical practice patterns to screen for prostate cancer in the United States.
We used the Behavioral Risk Factor Surveillance System 2010 data set to analyze geographic variability (by state) and its associated predictors in receiving a PSA test and/or a digital rectal examination (DRE). The study population consisted of men aged ≥50 years who responded as yes/no when asked about having a PSA test or DRE performed during the last year. We build two multilevel logistic regression models, differing in dependent variables, that is, (1) any prostate cancer screening (PCS) (either PSA and/or DRE), and (2) PCS based on PSA testing (PSAT). Individual characteristics (age, education, employment, marriage, income, race/ethnicity, self-reported health status, obesity, alcohol consumption, smoking status, personal physician presence, and health insurance coverage) were treated as level-1 variables and state characteristics (number of doctors per 100 000 persons per state, US regions and metropolitan statistical area (MSA) codes) were treated as level-2 variables.
We found significant geographic variability in receiving PCS and PSAT screening in the United States. For PCS, MSA code was an independent predictor, with men living in urban areas having lower odds of screening (odds ratio (OR)=0.8, 95% confidence interval (CI)=0.7-0.9). In PSAT, the number of doctors per 100 000 persons per state was an independent predictor, with lowest quartile states (0-25% quartile) having lower odds of PSA-based screening (OR=0.78, 95% CI=063-0.94). In both models, all level-1 variables were independent predictors (P<0.05) of PCS, except self-reported health status.
Men living in urban areas and states with lower prevalence of doctors have lower odds of screening for prostate cancer and PSAT, respectively, after adjusting for individual variables. Future studies should examine the reasons for these health disparities.
据我们所知,以前没有研究在美国检查前列腺癌的临床实践模式中检查过州级地理变异性及其预测因素。
我们使用行为风险因素监测系统 2010 年数据集来分析接受 PSA 测试和/或数字直肠检查(DRE)的地理变异性(按州划分)及其相关预测因素。研究人群由年龄≥50 岁的男性组成,他们在回答过去一年是否进行过 PSA 测试或 DRE 时回答了是/否。我们构建了两个不同因变量的多级逻辑回归模型,即(1)任何前列腺癌筛查(PCS)(PSA 和/或 DRE),以及(2)基于 PSA 检测的 PCS(PSAT)。个体特征(年龄、教育、就业、婚姻、收入、种族/民族、自我报告的健康状况、肥胖、饮酒、吸烟状况、有私人医生和医疗保险覆盖)被视为一级变量,州特征(每 10 万人中医生人数、美国地区和大都市统计区(MSA)代码)被视为二级变量。
我们发现美国在接受 PCS 和 PSAT 筛查方面存在显著的地理变异性。对于 PCS,MSA 代码是一个独立的预测因素,居住在城市地区的男性筛查的可能性较低(优势比(OR)=0.8,95%置信区间(CI)=0.7-0.9)。在 PSAT 中,每 10 万人中医生人数是一个独立的预测因素,最低四分位数州(0-25%四分位数)基于 PSA 的筛查可能性较低(OR=0.78,95%CI=0.63-0.94)。在两个模型中,除自我报告的健康状况外,所有一级变量都是 PCS 的独立预测因素(P<0.05)。
在调整个体变量后,居住在城市地区和医生患病率较低的州的男性接受前列腺癌和 PSAT 筛查的可能性较低。未来的研究应该研究这些健康差异的原因。